Research any topic before you write.

Find related topics. | Discover entities. | See connections. | Build a topical map.

Crizotinib: Community, Culture, Applications & Research

Crizotinib, sold under the brand name Xalkori among others, is an anti-cancer medication used for the treatment of non-small cell lung carcinoma (NSCLC). Crizotinib inhibits the c-Met/Hepatocyte growth factor receptor (HGFR) tyrosine kinase, which is involved in the oncogenesis of a number of other histological forms of malignant neoplasms. It also acts…

Language: English [EN]
Use the mouse wheel or two fingers (on touchscreens) to zoom in and out of the map.
100%
More settings
100% 100% 100% 100% 100%

Crizotinib topic overview

The analysis highlights Community, Culture, Applications and Research as prominent areas in the source structure around Crizotinib.

Related topics
35
Source areas
5
Connected nodes
40
Extracted relationships
115
Concept neighborhoods
15
Bridge connections
40

What this topic covers Research coverage

Source areas are shown by the number of related topics found in each part of the analysis. Use smaller areas too: they can reveal specialized angles and content gaps.

Mechanism of action · 14 topics
Overview · 10 topics
Society and culture · 6 topics
Research · 4 topics
Medical uses · 1 topics

Smaller areas are not necessarily less important. They contain fewer connections in this analysis and can be useful for finding specialized angles or coverage gaps.

Key facts & relationships

High-confidence facts extracted from structured source data. Use them as anchors for further research.

3D model (JSmol)
Interactive image
AHFS/Drugs.com
Monograph
ATC code
L01ED01 (WHO)
Bioavailability
43%
CAS Number
877399-52-5 N
ChEBI
CHEBI:64310 N

Explore all related topics Closing gaps

Browse the complete topic structure, not only the most central items. Less prominent entities and concepts can reveal missing angles, specialized context and useful research gaps. Each item opens a new analysis centered on that subject.

Overview

Medical uses

Mechanism of action

Society and culture

Research

Advanced semantic analysis

Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.

How Crizotinib connects Entity context

The extracted context around Crizotinib shows recurring relationship patterns in the source. For example, Crizotinib → ALK, An Investigational Drug, Anaplastic Large Cell Lymphoma, Brentuximab Vedotin, C-Met/Hepatocyte Growth Factor Tyrosine, Cancer, Cisplatin Or Carboplatin In, Clinical, Clinical Trial Testing The, ClinicalTrials, Combination Chemotherapy, Diagnosed Stage II-IV Anaplastic, Efficacy Of Crizotinib Versus, Gene, In Patients With Advanced, Kinase Inhibitor, Large Cell Lymphoma, National Cancer Institute, NCI Drug Dictionary, NCT00585195 Another extracted example is Crizotinib → ALK, Approval, Drug Administration, EMA, EML4-ALK, European Medicines Agency, FDA, In August, In March, In October, ROS1-positive, US Food. Use these groups to spot repeated connection types before inspecting the individual relationships.

Crizotinib

Top relations

related to External links · 41
Crizotinib → ALK, An Investigational Drug, Anaplastic Large Cell Lymphoma, Brentuximab Vedotin, C-Met/Hepatocyte Growth Factor Tyrosine, Cancer, Cisplatin Or Carboplatin In, Clinical, Clinical Trial Testing The, ClinicalTrials, Combination Chemotherapy, Diagnosed Stage II-IV Anaplastic, Efficacy Of Crizotinib Versus, Gene, In Patients With Advanced, Kinase Inhibitor, Large Cell Lymphoma, National Cancer Institute, NCI Drug Dictionary, NCT00585195
related to Legal status · 12
Crizotinib → ALK, Approval, Drug Administration, EMA, EML4-ALK, European Medicines Agency, FDA, In August, In March, In October, ROS1-positive, US Food
related to Lung cancer · 10
Crizotinib → Additionally, ALK, ALK-positive NSCLC, Approximately, Most, Phase III, PROFILE, Some, They, Tumors
related to Mechanism of action · 9
Crizotinib → About, ALK, ALK-fusion NSLC, ATP-binding, EGFR, EML4, K-Ras, Patients, The
related to Medical uses · 6
Crizotinib → ALCL, ALK, ALK-positive, IMT, It, NSCLC
Legal status · 5
Crizotinib → AU: S4 (Prescription only), CA: ℞-only, EU: Rx-only, UK: POM (Prescription only), US: ℞-only
related to Lymphomas · 4
Crizotinib → ALK, In, No, Treatment
3D model (JSmol) · 1
Crizotinib → Interactive image
AHFS/Drugs.com · 1
Crizotinib → Monograph
ATC code · 1
Crizotinib → L01ED01 (WHO)

Important terminology

Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.

Important terminology

kinase alk lymphoma lung cell treatment non-small anaplastic cancer malignant patients gene number tumors fusion nsclc growth also refractory factor

Crizotinib relationships Subject–Predicate–Object triples

TTTA extracted 115 structured relationships around Crizotinib. Examples in this analysis include Crizotinib → 3D model (JSmol) → Interactive image and Crizotinib → AHFS/Drugs.com → Monograph. The table shows each extracted connection, where it came from and its confidence.

SubjectPredicateObjectConfidenceSrc
Crizotinib3D model (JSmol)Interactive image1.00infobox
CrizotinibAHFS/Drugs.comMonograph1.00infobox
CrizotinibATC codeL01ED01 (WHO)1.00infobox
CrizotinibBioavailability43%1.00infobox
CrizotinibCAS Number877399-52-5 N1.00infobox
CrizotinibChEBICHEBI:64310 N1.00infobox
CrizotinibChEMBLChEMBL601719 Y1.00infobox
CrizotinibChemSpider9801307 Y1.00infobox
CrizotinibCompTox Dashboard (EPA)DTXSID7010093291.00infobox
CrizotinibDrugBankDB08700 Y1.00infobox
CrizotinibECHA InfoCard100.166.4401.00infobox
CrizotinibElimination half-life42 hours1.00infobox
CrizotinibExcretionFaeces (63%), urine (22%)1.00infobox
CrizotinibFormulaC21H22Cl2FN5O1.00infobox
CrizotinibIUPHAR/BPS49031.00infobox
CrizotinibKEGGD09731 N1.00infobox
CrizotinibLegal statusAU: S4 (Prescription only)1.00infobox
CrizotinibLegal statusCA: ℞-only1.00infobox
CrizotinibLegal statusUK: POM (Prescription only)1.00infobox
CrizotinibLegal statusUS: ℞-only1.00infobox
CrizotinibLegal statusEU: Rx-only1.00infobox
CrizotinibLicense dataUS DailyMed: Crizotinib1.00infobox
CrizotinibMedlinePlusa6120181.00infobox
CrizotinibMetabolismLiver (CYP3A4/CYP3A5-mediated)1.00infobox
CrizotinibMolar mass450.34 g·mol−11.00infobox
CrizotinibOther namesPF-02341066 10661.00infobox
CrizotinibPDB ligandVGH (PDBe, RCSB PDB)1.00infobox
CrizotinibPregnancy categoryAU: D1.00infobox
CrizotinibProtein binding91%1.00infobox
CrizotinibPubChem CID116265601.00infobox

Related concept clusters Concept neighborhoods

The concept neighborhoods around Crizotinib bring nearby vocabulary together. In this analysis, examples include Cell, Lung and Non-small. Use the clusters to find adjacent concepts and terminology that may deserve separate research.

  • Crizotinib
    • Cell
    • Lung
    • Non-small
    • Kinase
    • Anaplastic
    • Alk
    • Lymphoma
    • Nsclc
    • Cancer
    • Gene
    • Treatment
    • Advanced
  • crizotinib
    • Cell
    • Lung
    • Non-small
    • Kinase
    • Anaplastic
    • Alk
    • Lymphoma
    • Nsclc
    • Cancer
    • Gene
    • Treatment
    • Advanced
  • non-small cell lung carcinoma
    • Non-small
    • Lung
    • Lymphoma
    • Anaplastic
    • Gene
    • Approved
    • Cancers
    • Alk
    • Large
    • Relapsed
    • Crizotinib
    • Kinase
  • tyrosine kinase
    • Alk
    • Lymphoma
    • Anaplastic
    • Gene
    • Inhibitor
    • Lung
    • Non-small
    • Advanced
    • Approved
    • Cancers
    • Drug
    • Protein
  • anaplastic lymphoma kinase
    • Lymphoma
    • Refractory
    • Alk
    • Cell
    • Anaplastic
    • Kinase
    • Non-small
    • Cancers
    • Large
    • Relapsed
    • Lung
    • Gene
  • protein kinase
    • Alk
    • Lymphoma
    • Anaplastic
    • Gene
    • Inhibitor
    • Lung
    • Non-small
    • Status
    • Xalkori
    • Advanced
    • Approved
    • Cancers
  • kinase
    • Alk
    • Lymphoma
    • Anaplastic
    • Gene
    • Inhibitor
    • Lung
    • Non-small
    • Advanced
    • Approved
    • Cancers
    • Drug
    • Protein
  • lung cancers
    • Non-small
    • Approved
    • Metastatic
    • Lymphoma
    • Gene
    • Cancers
    • Lung
    • Anaplastic
    • Cell
    • Alk
    • Kinase
    • Legal

Connections between topic areas Semantic bridges

For Crizotinib, one of the stronger structural bridges in this analysis connects Crizotinib with Mechanism of action. Bridges highlight paths between different parts of the map and can reveal research angles that are easy to miss in a flat list.

Min side: 3
CrizotinibMechanism of action · splits 26 ⟂ 15
CrizotinibOverview · splits 30 ⟂ 11
CrizotinibSociety and culture · splits 34 ⟂ 7
CrizotinibResearch · splits 36 ⟂ 5

Map overview Semantic statistics

Crizotinib

Nodes41
Edges40
Triples115
Avg. degree1.95
Density0.04878
Components1

Source & methodology

TTTA analyzes the structure around Crizotinib to surface related topics, entities, relationships, concept neighborhoods and bridge connections. Use the map to explore areas such as Community, Culture, Applications & Research, including less central topics that may reveal useful research gaps. Automatically extracted connections are research leads rather than rewritten encyclopedia content.

Source: Wikipedia — Crizotinib · EN edition · Analysis: TopicsToTalkAbout

For writers, content strategists, SEOs, marketers and creators — from quick topic research to advanced semantic analysis.